Following on from last year, Beckley Psytech will again attend the Jefferies London Healthcare Conference and will hold a formal company presentation.

All equity acquisition adds short-acting psilocin candidate for broad range of indications to Beckley Psytech's portfolio of psychedelic assets. Expanded clinical pipeline will deliver multiple value inflection points over next 18 months. Phase 1 single ascending dose study of ELE-101 to initiate before the end of 2022. Lead 5-MeO-DMT formulation BPL-003 selected for upcoming Phase 2 studies in depression.

We are happy to announce the arrival of Ruth Bateson as Senior Director, Clinical Operations and Charlotte Chorley as Communications Lead.

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.